Redirecting T cells to glypican-3 with 28.41BB.ζ and 28.ζ-41BBL CARs for hepatocellular carcinoma treatment

Haili Ma, Siye Chen, Yan He, Jingwei Huang, Yanhong Xu, Chao Wang, Cheng Lei, Ting Lu, Shengdong Xiao, Jinming Mao, Yiyun Xu, Hao Guo, Bohua Li, Minghui Zhang, Xiaowen He

PDF(1376 KB)
PDF(1376 KB)
Protein Cell ›› 2018, Vol. 9 ›› Issue (7) : 664-669. DOI: 10.1007/s13238-017-0489-0
LETTER

Redirecting T cells to glypican-3 with 28.41BB.ζ and 28.ζ-41BBL CARs for hepatocellular carcinoma treatment

Author information +
History +

Cite this article

Download citation ▾
Haili Ma, Siye Chen, Yan He, Jingwei Huang, Yanhong Xu, Chao Wang, Cheng Lei, Ting Lu, Shengdong Xiao, Jinming Mao, Yiyun Xu, Hao Guo, Bohua Li, Minghui Zhang, Xiaowen He. Redirecting T cells to glypican-3 with 28.41BB.ζ and 28.ζ-41BBL CARs for hepatocellular carcinoma treatment. Protein Cell, 2018, 9(7): 664‒669 https://doi.org/10.1007/s13238-017-0489-0

References

[1]
Ahmed N, Brawley VS, Hegde M (2015) Human Epidermal Growth Factor Receptor 2 (HER2)-Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol 33(15):1688–1696
CrossRef Google scholar
[2]
Dredge K, Marriott JB, Todryk SM, Dalgleish AG (2015) Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy. Cancer Immunol Immunother 51(10):521–531
CrossRef Google scholar
[3]
Gao H, Li K, Tu H (2014) Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res 20(24):6418–6428
CrossRef Google scholar
[4]
Gilham DE, Debets R, Pule M, Hawkins RE, Abken H (2012) CAR–T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med 18(7):377–384
CrossRef Google scholar
[5]
Grupp SA, Kalos M, Barrett D (2013) Chimeric antigen receptormodified T cells for acute lymphoid leukemia. N Engl J Med 368 (16):1509–1518
CrossRef Google scholar
[6]
Kalos M, Levine BL, Porter DL (2011) Tcells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3(95):95ra73
CrossRef Google scholar
[7]
Kohler BA, Sherman RL, Howlader N, (2015) Annual Report to the Nation on the Status of Cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst 107(6)
CrossRef Google scholar
[8]
Li W, Guo L, Rathi P,Marinova E, Gao X, Wu MF, Liu H, Dotti G, Gottschalk S,Metelitsa LS,Heczey A (2016) Redirecting T Cells toGlypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity. Hum Gene Ther2016 Aug 16
[9]
Mannino MH, Zhu Z, Xiao H, Bai Q, Wakefield MR, Fang Y (2015) The paradoxical role of IL-10 in immunity and cancer. Cancer Lett 367 (2):103–107
CrossRef Google scholar
[10]
Maude SL, Frey N, Shaw PA (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371 (16):1507–1517
CrossRef Google scholar
[11]
Pule MA, Savoldo B,Myers GD (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence andantitumor activity in individuals with neuroblastoma. Nat Med 14 (11):1264–1270
CrossRef Google scholar
[12]
Sato T, Terai M, Tamura Y, Alexeev V, Mastrangelo M, Selvan S (2011) Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res 51(2–3):170–182
CrossRef Google scholar
[13]
Taub DD, Anver M, Oppenheim JJ, Longo DL, Murphy WJ (1996) T lymphocyte recruitment by interleukin-8 (IL-8). IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo. J Clin Invest 97(8):1931–1941
CrossRef Google scholar
[14]
Zhao Zeguo, Condomines Maud, van der Stegen Sjoukje JC, Perna Fabiana, Kloss Christopher C, Gunset Gertrude, Plotkin Jason, Sadelain Michel (2015) Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. Cancer Cell 28:415–428
CrossRef Google scholar
[15]
Zhu AX, Gold PJ, El-Khoueiry AB (2013) First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res 19(4):920–928
CrossRef Google scholar

RIGHTS & PERMISSIONS

2017 The Author(s) 2017. This article is an open access publication
AI Summary AI Mindmap
PDF(1376 KB)

Accesses

Citations

Detail

Sections
Recommended

/